Corcept Therapeutics

Historical price data

Corcept Therapeutics has successfully transitioned from a research entity to a fully integrated commercial organization, anchored by its FDA-approved product Korlym® for hypercortisolism. Its core strategy leverages a proprietary platform of selective cortisol modulators, recently validated by the FDA approval of relacorilant (Lifyorli®) for platinum-resistant ovarian cancer. With over 30 ongoing studies across endocrinology, oncology, metabolism, and neurology, Corcept is pursuing a focused, independent path to expand the therapeutic reach of its unique mechanism.

Proprietary platform for the discovery and development of selective cortisol modulators—small molecules that precisely regulate cortisol activity at the glucocorticoid receptor (GR) to treat serious diseases.